1. Generics Bulletin
  2. >>Business
  3. >>Deals

Alvotech And Stada Are Back With A Denosumab Biosimilar Deal

The Duo Initially Started Their Biosimilar Partnership In 2019

 
• By Urtė Fultinavičiūtė

With an ustekinumab biosimilar launch in Europe just around the corner, Alvotech and Stada have reconsidered the previously dropped denosumab partnership, while commercial rights to the aflibercept biosimilar go back to Alvotech.

Red paper plane changing its direction back
• Source: Shutterstock

Alvotech and Stada are back on track with a fresh marketing license deal for the former’s biosimilar rival to Amgen’s denosumab brands Prolia and Xgeva, despite previously terminating their licensing and supply partnership for three of Alvotech’s biosimilars, including denosumab. 

Last May, Alvotech announced that it had terminated agreements with Stada on three biosimilars – AVT03 denosumab, AVT05 golimumab,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Hyloris Strikes New Deals With AFT And QliniQ Over Novel Valacyclovir Formulation

 
• By Adam Zamecnik

The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

More from Business

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.